Crosby J*, Peloso GM,* Auer PL*, TG and HDL Working Group of the Exome Sequencing Project, National, Heart, Lung, and Blood Institute, Reiner AP*, Boerwinkle E*, Kathiresan S*. In a large-scale population-based exome sequencing study for plasma lipids, we discovered that people who carry rare mutations that reduce the production of the APOC3 protein have …
The future of heart attack prevention could be as easy as a single injection
Heart attacks and strokes remain the world’s biggest killers. This year, we’ll see test results on new cardiovascular treatments that cut cholesterol even more than…
The future of heart attack prevention could be as easy as a single injection
Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative to conventional CRISPR. Clinical results have…
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year…
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year…
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year…
This mendelian randomization analysis estimates the magnitude of the change in plasma lipoprotein(a) levels needed to have the same evidence of an association with coronary…
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
The Investor Relations website contains information about Verve Therapeutics’s business for stockholders, potential investors, and financial analysts.
